Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1

Bortezomib (Velcade) is used widely for the treatment of various human cancers; however, its mechanisms of action are not fully understood, particularly in myeloid malignancies. Bortezomib is a selective and reversible inhibitor of the proteasome. Paradoxically, we find that bortezomib induces prote...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Fang, Jing, Rhyasen, Garrett, Bolanos, Lyndsey, Rasch, Christopher, Varney, Melinda, Wunderlich, Mark, Goyama, Susumu, Jansen, Gerrit, Cloos, Jacqueline, Rigolino, Carmela, Cortelezzi, Agostino, Mulloy, James C., Oliva, Esther N., Cuzzola, Maria, Starczynowski, Daniel T.
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society of Hematology 2012
الموضوعات:
Myeloid Neoplasia
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3412348/
https://ncbi.nlm.nih.gov/pubmed/22685174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-02-407999
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة